PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome: However, upon a more detailed examination of those research findings, the efficacy of PARP inhibitors is less evident in patients without BRCA mutations or HRD, compared to those with BRCA mutations or Homologous Recombination Deficiency (HRD).